Vertex, CRISPR and Bluebird Bio Receive FDA Approval for Two Gene Therapies for Sickle Cell

For Immediate Release: December 08, 2023 Today, the U.S. Food and Drug Administration approved two milestone treatments, Casgevy and Lyfgenia, representing the first cell-based gene [...]

2023-12-08T12:43:22-07:00December 8, 2023|

KromaTiD and SeQure Dx Partnership Agreement Offers Comprehensive IND-Enabling Gene Editing Services

  KromaTiD and SeQure Dx enter partnership agreement to offer comprehensive, IND-enabling gene editing services supporting cell and gene therapy research Longmont, CO. and Waltham, [...]

2023-11-30T15:12:59-07:00November 30, 2023|


Go to Top